Answers are grounded in this paper and cite their sources.
Existing data do not clearly define the role of Osimertinib in the treatment of resected EGFR-mutated lung cancer. We present the case of a patient with stage IIIA EGFR exon 19 deletion positive NSCLC whose disease was pathologically down staged by neoadjuvant chemoradiation. Future trials should include such patients to inform decisions about adjuvant treatment with respect to survival benefit and toxicity.
No takes yet. Share an insight, caveat, or question.
DeCarli et al. (2022) studied this question.
Synapse has enriched 9 related papers. Consider them for comparative context: